Stringent regulatory environments can make OEMs reluctant to change processes and materials for approved medical devices
Patni brings over 25 years of distinguished experience in the pharmaceutical industry
The emergence of new infections in India is a growing concern
The company is also looking at an inorganic opportunity over the next two years to have a commercially ready footprint in the US
This marks the first regulatory approval worldwide for nasally-delivered epinephrine
The clinical trial will be conducted at 19 sites with 10,335 participants across India
Capital expenditure expected to moderate to Rs. 5.6 billion in FY2025 from an estimated Rs. 7.6 billion in FY2024
Gross profit was Rs. 328.8 crore, up by 27.8% YoY with a gross margin expansion of 418 bps to 55.7%
He recently served as Senior Vice President of the API business at Shilpa Pharma Life Sciences for over 3 years
Subscribe To Our Newsletter & Stay Updated
